Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg
These 5 growth stocks are now in buy ranges

Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase. 

With the recent uptrend in large-cap stocks, as reflected by the performance of

These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg
These 5 growth stocks are now in buy ranges

Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase. 

With the recent uptrend in large-cap stocks, as reflected by the performance of

Verizon and AT&T: One is a high-yield value, the other a trap: https://www.marketbeat.com/logos/articles/med_20240124114037_chart-vz-att-1242023ver001.png
Verizon and AT&T: One is a high-yield value, the other a trap

Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T) have presented value and yield to investors for years. 

However, they failed to sustain interest in their stocks, creating a drag on

Verizon and AT&T: One is a high-yield value, the other a trap: https://www.marketbeat.com/logos/articles/med_20240124114037_chart-vz-att-1242023ver001.png
Verizon and AT&T: One is a high-yield value, the other a trap

Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T) have presented value and yield to investors for years. 

However, they failed to sustain interest in their stocks, creating a drag on

These 5 growth stocks are now in buy ranges: https://www.marketbeat.com/logos/articles/med_20240125065914_these-5-growth-stocks-are-now-in-buy-ranges.jpg
These 5 growth stocks are now in buy ranges

Chart patterns and consolidations are worth watching, as they provide actionable guidance for making a purchase. 

With the recent uptrend in large-cap stocks, as reflected by the performance of

Food fight! Which grocery store stocks will win in 2024?: https://www.marketbeat.com/logos/articles/med_20240124122319_food-fight-which-grocery-store-stocks-will-win-in.jpg
Food fight! Which grocery store stocks will win in 2024?

Food distributors and retailers are living up to their reputation as the best consumer staples industry to own. 

Up 2.1% year-to-date, the group has a sizable early lead over its roughly flat sec

Intuitive Surgical’s post-earnings dip is a healthy time to buy: https://www.marketbeat.com/logos/articles/med_20240124145004_chart-isrg-1242024ver001.png
Intuitive Surgical’s post-earnings dip is a healthy time to buy

Intuitive Surgical (NASDAQ: ISRG) share prices surged following the Q4 release but failed to hold the gain, creating an ugly candle capping a strong rally. The market may move lower from here, but

Intuitive Surgical’s post-earnings dip is a healthy time to buy: https://www.marketbeat.com/logos/articles/med_20240124145004_chart-isrg-1242024ver001.png
Intuitive Surgical’s post-earnings dip is a healthy time to buy

Intuitive Surgical (NASDAQ: ISRG) share prices surged following the Q4 release but failed to hold the gain, creating an ugly candle capping a strong rally. The market may move lower from here, but

5 top healthcare stocks for earnings growth in 2024: https://www.marketbeat.com/logos/articles/med_20240124120518_5-top-healthcare-stocks-for-earnings-growth-in-202.jpg
5 top healthcare stocks for earnings growth in 2024

While the healthcare sector delivered lackluster profit growth in 2023, it should change this year. 

Sector components forecast to show the biggest earnings year-over-year earnings improvement

Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg
Why Apple’s about to smash through $200 and continue

Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make

Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg
Why Apple’s about to smash through $200 and continue

Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make

Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg
Why Apple’s about to smash through $200 and continue

Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make

Why Apple’s about to smash through $200 and continue: https://www.marketbeat.com/logos/articles/med_20240124111807_why-apples-about-to-smash-through-200-and-continue.jpg
Why Apple’s about to smash through $200 and continue

Microsoft Corporation (NASDAQ: MSFT) recently overtook Apple Inc. (NASDAQ: AAPL) as the world's most valuable company while also setting its all-time high; expectations are high for Apple to make

Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png
Will leverage and pricing power drive Netflix to a record high?

The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by

Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png
Will leverage and pricing power drive Netflix to a record high?

The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by

Will leverage and pricing power drive Netflix to a record high?: https://www.marketbeat.com/logos/articles/med_20240124071952_chart-nflx-1242024ver001.png
Will leverage and pricing power drive Netflix to a record high?

The Netflix Inc. (NASDAQ: NFLX) narrative is not without risk. The company struggled with growth following the COVID-19 bubble, but those days are behind. The story today is leverage, driven by

Is it a logical time to buy Logitech?: https://www.marketbeat.com/logos/articles/med_20240124083605_chart-logi-1242024ver001.png
Is it a logical time to buy Logitech?

Shares of Logitech International S.A. (NASDAQ: LOGI) fell sharply despite a solid earnings report and improved guidance. The move took share prices to a two-month low, setting up an attractive

3 just-upgraded energy stocks to put on your radar: https://www.marketbeat.com/logos/articles/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg
3 just-upgraded energy stocks to put on your radar

Last night saw the S&P 500 index close at a fresh all-time high. It's a remarkable achievement that didn't look as likely as recently as October. But since the prospect of a rate cut became quite

3 just-upgraded energy stocks to put on your radar: https://www.marketbeat.com/logos/articles/med_20240124085415_3-just-upgraded-energy-stocks-to-put-on-your-radar.jpg
3 just-upgraded energy stocks to put on your radar

Last night saw the S&P 500 index close at a fresh all-time high. It's a remarkable achievement that didn't look as likely as recently as October. But since the prospect of a rate cut became quite

Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal.  Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech

 

24.01.24

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Link

Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal.  Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech

 

24.01.24

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Link

Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal.  Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73356/Aktiencheck240124_01.001.png
Eilt: Institutionelle Investoren begeistert von innovativer Krebstherapie. Massives Kaufsignal. Neuer 199% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Großinvestoren begeistert von innovativer Krebstherapie. Neuer 199% Biotech Aktientip nach 15.973% mit BioNTech

 

24.01.24

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Link